What is Exenatide?
Exenatide is an incretin medicine used in type 2 diabetes. Short-acting and extended-release products need to be distinguished when reading evidence.
Biological role or research focus
Glucose-dependent insulin signaling.
Its established clinical context is type 2 diabetes, with formulation-specific precautions.
Role reference: MedlinePlus · Exenatide ↗
Names you may encounter
Byetta · Bydureon
Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.
- Class / identity
- GLP-1 receptor agonist
- Main research area
- Type 2 diabetes
- Evidence featured
- Human randomized trial
- Source check
- October 4, 2026
Source: MedlinePlus · Exenatide ↗
Quick answers
- Is Exenatide FDA approved?
- Yes. Byetta (NDA 021919 listed as prescription) for type 2 diabetes. Source ↗
- Is Exenatide safe?
- Approved GLP-1 drug for type 2 diabetes; stomach upset is common, with risks of pancreatitis, low blood sugar alongside other diabetes drugs, and rare immune-related low platelets. Human safety data: its FDA label lists the known risks. The Risks & interactions section below lists what is known. Read the risks ↓
- Is Exenatide banned in sport?
- It is not named on the 2026 World Anti-Doping Agency (WADA) Prohibited List. Athletes should still check with their sport’s anti-doping body. Source ↗
- Has the FDA taken action over Exenatide?
- Yes. Our records list 1 FDA action naming it, most recently on November 9, 2026: FDA Drug Safety Communication requiring all GLP-1 receptor agonist labels to add a warning about a potential increased risk of NAION (non-arteritic anterior ischemic optic neuropathy), a rare optic nerve condition that can cause sudden, painless vision loss in one eye, including permanent loss. Source ↗
What does the evidence show?
Evidence map
Every study featured on this page, grouped by what was actually tested. Human studies count most; animal and cell results often do not carry over to people.
| Study | Type | Population / model |
|---|---|---|
| EXSCEL (2017) | Human randomized trial | 14,752 adults with type 2 diabetes. |
| Phase 3 Parkinson disease trial (2025) | Human phase 3 randomized trial | 194 people aged 25–80 with Parkinson disease were randomized equally at six UK hospitals; 188 had follow-up data included in analyses. |
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Human randomized trial · 2017
EXSCEL
Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes.
- Population / model
- 14,752 adults with type 2 diabetes.
- Study design
- Once-weekly exenatide versus placebo; cardiovascular outcomes followed over a median 3.2 years.
- Main finding
- The main cardiovascular composite occurred in 11.4% versus 12.2%; hazard ratio 0.91 (95% CI 0.83–1.00). Noninferiority was met, but superiority was not (P=0.06).
- How to read it
- The 0.8-percentage-point observed event difference is descriptive. The primary superiority test was not significant, so EXSCEL cannot be presented as a proven cardiovascular-event reduction.
- Limits & context
- Meeting a cardiovascular safety criterion is different from proving cardiovascular benefit. Results concern the once-weekly preparation and should not be relabeled as an obesity trial.
Source: Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. ↗
Human phase 3 randomized trial · 2025
Phase 3 Parkinson disease trial
Did extended-release exenatide slow Parkinson motor progression?
- Population / model
- 194 people aged 25–80 with Parkinson disease were randomized equally at six UK hospitals; 188 had follow-up data included in analyses.
- Study design
- Double-blind placebo comparison for 96 weeks on top of dopaminergic treatment. The primary motor score was assessed off dopaminergic medication.
- Main finding
- MDS-UPDRS part III off-medication scores worsened by 5.7 points with exenatide versus 4.5 with placebo. Adjusted treatment coefficient: 0.92 (95% CI −1.56 to 3.39; P=0.47). At least one serious adverse event occurred in 9% versus 11%.
- How to read it
- The larger phase 3 study did not support a disease-modifying effect in this population. Earlier mechanistic or small-study signals should be read alongside this negative result.
- Limits & context
- This result concerns exenatide, the studied population, and the specified endpoint. It does not prove that every GLP-1 agent has identical neurological effects. A nonsignificant result also does not prove exact equivalence or absence of rare harms.
Source: Exenatide phase 3 Parkinson trial · The Lancet · 2025 ↗
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Registered human trials
58 registered studies name Exenatide as an intervention among the 100 most recently updated of 381 search results; 5 are recruiting or under way, 0 have not started recruiting yet, 41 completed and 12 ended early, were withdrawn or have another status. Checked November 16, 2026 on ClinicalTrials.gov.
A registration shows a study was planned; it is not a result. Some studies use the compound only as a comparison or in a combination. All 58 listed studies.
Search additional PubMed records ↗Risks & interactions
Approved GLP-1 drug for type 2 diabetes; stomach upset is common, with risks of pancreatitis, low blood sugar alongside other diabetes drugs, and rare immune-related low platelets.
This entry follows the Byetta label, which has no boxed warning; other exenatide products have separate labels that may differ. Safety comes from controlled diabetes trials and postmarketing reports.
Take extra care with: Blood thinners or bleeding problemsDiabetes or blood-sugar medicinesKidney problems
From the FDA label lists below. If a condition applies to you, talk to a doctor or pharmacist first. Each tag opens every profile that mentions it.
Who should not use it
- Past severe allergic reaction to exenatide or any ingredient
- Past drug-induced immune low platelet count (thrombocytopenia) from exenatide
- Not recommended with severe gastroparesis (label warning)
Interactions
- Insulin or sulfonylureas: higher risk of low blood sugar
- Warfarin: reports of increased INR, sometimes with bleeding
- Oral medicines such as acetaminophen: slowed stomach emptying can delay absorption
Serious risks
- Acute pancreatitis, including fatal forms
- Immune-related low platelets causing serious, possibly fatal, bleeding
- Kidney injury from dehydration due to vomiting or diarrhea
- Antibodies that may weaken blood sugar control
- Gallbladder disease; serious allergic reactions
- Inhaling stomach contents during anesthesia or deep sedation
Common side effects
- nausea
- low blood sugar
- vomiting
- diarrhea
- feeling jittery
- dizziness
- headache
- indigestion
Summarized from the FDA label with AI assistance; not reviewed by a clinician. Not a complete list, and not medical advice: talk to a doctor or pharmacist about your own situation. Checked 2026-10-10. Sources: DailyMed: Byetta (exenatide) prescribing information ↗
Key precautions
Gastrointestinal effects, pancreatitis concerns, kidney-related precautions, and medication interactions matter. Product-specific warnings may differ between preparations, so the exact label is essential.
Source: MedlinePlus · Exenatide ↗
Regulatory status
- U.S. FDA approval
- Approved
Byetta (NDA 021919 listed as prescription) for type 2 diabetes. Bydureon, Bydureon BCise and the earlier Byetta application (NDA 021773) are listed as discontinued. source - FDA compounding (503A bulk list)
- Not on FDA’s compounding lists
Not on FDA's 503A nominated-substance category lists. As a component of an FDA-approved drug it does not need to be on the 503A bulks list to be used in pharmacy compounding (other 503A conditions still apply). source - World Anti-Doping Agency (2026)
- Not on the WADA Prohibited List
Not named and not within a prohibited class on the 2026 List. source
FDA actions
- FDA Drug Safety Communication requiring all GLP-1 receptor agonist labels to add a warning about a potential increased risk of NAION (non-arteritic anterior ischemic optic neuropathy), a rare optic nerve condition that can cause sudden, painless vision loss in one eye, including permanent loss. Across 126 randomized trials (134,253 patients), NAION occurred 6.4 times per 100,000 person-years on GLP-1 drugs versus 3.8 on placebo or other diabetes drugs. FDA advises patients to contact a health care professional right away if they notice sudden vision loss in one eye, blind spots, color distortion or blurry spots, and says anyone who has had NAION should talk with their health care professional about whether to continue the medicine. (2026-11-09) source
Other notes
- Exenatide is one of the GLP-1 active ingredients covered by FDA Import Alert 66-80 (detention without physical examination of GLP-1 bulk drug substances from non-green-listed makers; revised September 2026). source
Checked October 28, 2026. Rules change; follow the source links for the current status. Regulatory tracker.
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
Clinical uses & product context
The medication reference describes diabetes care alongside diet and exercise. EXSCEL specifically tested a once-weekly preparation for cardiovascular outcomes; its safety finding should not be relabeled as a demonstrated superiority benefit.
Source: MedlinePlus · Exenatide ↗
New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Sources & supplier listings
PepsRadar does not list, compare or link GLP-1-class products, even though some sellers we track elsewhere on the site also sell them. The approved medicine is available only with a prescription, through a pharmacy. The FDA warns that versions sold online as "research" products are unapproved and of unknown quality (FDA).
Mechanism & research rationale
It promotes insulin release when glucose is elevated. This supports glucose management, but does not by itself establish a reduction in cardiovascular events.
Source: MedlinePlus · Exenatide ↗
Molecular structure
Questions worth asking
- Which indication and formulation does the source describe?
- Does the video make a broader claim than the source supports?
- Its established clinical context is type 2 diabetes, with formulation-specific precautions.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Video & podcast discussions: members library
Frequently asked questions
Did EXSCEL prove fewer cardiovascular events?
It met the prespecified noninferiority safety test, but not the superiority test.
Source: MedlinePlus · Exenatide ↗
Can all exenatide products be substituted by name?
No. Release characteristics and product instructions differ.
Source: Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. ↗
Can a promising GLP-1 mechanism establish treatment for Parkinson disease?
No. Laboratory rationale must be tested against clinical outcomes. The 2025 exenatide phase 3 trial did not demonstrate slowed motor progression at 96 weeks.
Source: Exenatide phase 3 Parkinson trial · The Lancet · 2025 ↗
Can the lixisenatide result replace the exenatide result?
No. These are different medicines, populations, durations, and assessment conditions. Separate trial results should remain attached to the studied compound.
Source: Exenatide phase 3 Parkinson trial · The Lancet · 2025 ↗
How complete is this evidence review?
This profile summarizes selected NLM abstracts and linked medicine information. It is not a systematic review. Full-text verification and a comprehensive search have not been done, and this summary has not been reviewed by a medical professional.
References & editorial record
- MedlinePlus · Exenatide ↗
- Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes. ↗
- Exenatide phase 3 Parkinson trial · The Lancet · 2025 ↗
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation.
